| Cat. No. |
Product Name |
CAS No. |
Information |
| GY02457 |
ACY-738
|
1375465-91-0 |
ACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs; induces dramatic increase in α-tubulin acetylation in brain and stimulates mouse exploratory behaviors; increases the innervation of the neuromuscular junctions in the gastrocnemius muscle and improves the motor and sensory nerve conduction in the mutant HSPB1-induced CMT2 mouse model. |
| GY07008 |
trans CM-414
|
1624792-73-9 |
trans CM-414 is a first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM); does not inhibit class IIa HDAC isoforms, MMP-3, MMP-10, and PDE9 (IC50>10 uM), has modest or weak activity for HDAC8/11/10 (IC50=640/550/2400 nM); diminishes brain Aβ and pTau levels, increases the inactive form of GSK3β, reverts the decrease in dendritic spine density on hippocampal neurons, and reverses the cognitive deficits in Tg2576 mice. |
| GY07007 |
cis CM-414
|
1624792-70-6 |
cis CM-414 is a first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM); does not inhibit class IIa HDAC isoforms, MMP-3, MMP-10, and PDE9 (IC50>10 uM), has modest or weak activity for HDAC8/11/10 (IC50=640/550/2400 nM); diminishes brain Aβ and pTau levels, increases the inactive form of GSK3β, reverts the decrease in dendritic spine density on hippocampal neurons, and reverses the cognitive deficits in Tg2576 mice. |
| GY07006 |
CM-414
|
2007971-51-7 |
CM-414 is a first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM); does not inhibit class IIa HDAC isoforms, MMP-3, MMP-10, and PDE9 (IC50>10 uM), has modest or weak activity for HDAC8/11/10 (IC50=640/550/2400 nM); diminishes brain Aβ and pTau levels, increases the inactive form of GSK3β, reverts the decrease in dendritic spine density on hippocampal neurons, and reverses the cognitive deficits in Tg2576 mice. |
| GY06952 |
SB-429201
|
1027971-34-1 |
SB-429201 is a potent, selective HDAC1 inhibitor with IC50 of 1.5 uM; increases histone acetylation in SW620 cells. |
| GY06951 |
SB-379278A
|
146366-04-3 |
SB-379278A is a potent and selective HDAC8 inhibitor with IC50 of 0.5 uM. |
| GY06950 |
NCC-149
|
1316652-41-1 |
NCC-149 is a potent and selective HDAC8 inhibitor with IC50 of 70 nM; displays high selectivity over major HDACs (HDAC1: IC50 38 uM, HDAC2 >100 uM, HDAC4: IC50: 44 uM,HDAC6: IC50 2.4 uM). |
| GY06949 |
HDAC8-IN-20a
|
1884231-52-0 |
HDAC8-IN-20a is a potent, selective HDAC8 inhibitor with IC50 of 27 nM; efficiently blocks the activation of growth receptor survival signaling and shifts the cell cycle arrest and differentiation phenotype toward effective cell death of neuroblastoma cell lines combined with crizotinib, efficiently kills neuroblastoma cell lines carrying wildtype ALK, amplified ALK and those carrying the activating ALK F1174L mutation, as well as cells carrying the activating R1275Q mutation. |
| GY10082 |
Class I and IIB HDAC inhibitor 42
|
2245323-24-2 |
Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor (HDAC1 Ki=0.27 nM) for topical treatment of cutaneous t-cell lymphoma. |
| GY10173 |
RTS-V5
|
|
RTS-V5 (Dual HDAC-proteasome inhibitor RTS-V5) is the first-in-class, dual HDAC-proteasome inhibitor with IC50 of 0.27 uM (HDAC6), inhibits HDAC8 (IC50=0.53 uM), and low activity against HDAC/1/2/3; demonstrates cytotoxicity against leukemia and multiple myeloma cell lines as well as therapy-refractory primary patient-derived leukemia cells. |
$ USD
Select Your Country or Region
